Saturday, March 13, 2010
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
RESULTS: .....Four patients were enrolled. After preoperative treatment and cytoreductive surgery, all patients were excluded from protocol due to severe toxicities. Three patients had life threatening events (cardiac output failure, myocardial infarction, anastomotic leak); two patients had primary progressive disease.
CONCLUSION: The addition of sorafenib to carboplatin/paclitaxel chemotherapy was not feasible within this neoadjuvant regimen in primary advanced ovarian cancer. Although the occurrence of serious adverse events might have emerged at random, a detrimental effect of preoperative study medication could not be denied. Further evaluations of sorafenib in ovarian cancer are warranted.
abstract/free full text: MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary
CONCLUSIONS/SIGNIFICANCE: High grade serous ovarian carcinomas with and without BRCA1/2 abnormalities demonstrate very similar miRNA expression profiles. High grade serous carcinomas as a group exhibit significant miRNA dysregulation in comparison to tubal epithelium and the levels of miR-34c and miR-422b appear to be prognostically important. full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749450/?tool=pubmed
abstract: Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?
In Research: Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets (Japan)
Patients with advanced-stage ovarian cancer generally undergo primary debulking surgery followed by platinum/taxane-based chemotherapy. Although postoperative introduction of taxane drug has improved the 5-year survival rate for advanced-stage ovarian cancer..... Clinicopathological characteristics, such as debulking status after primary surgery, are clinically considered important indicators of prognosis. However, recurrence after optimal debulking surgery occurs in some patients, while disease-free status after incomplete surgery is maintained in others......Therefore, these clinicopathological factors alone are insufficient for predicting prognosis and elucidating the pathological mechanisms of disease progression or recurrence. Molecular biology approaches can be used to identify new prognosis-related profiles leading to elucidation of pathological issues of advanced-stage serous ovarian cancer.
Meanwhile, there are no microarray kits for clinical diagnosis and management in patients with ovarian cancer yet."
TORONTO -- 03/12/10 -- The Ontario Institute for Cancer Research (OICR) today announced a significant investment toward the development of two new promising cancer therapies. The recipients of the awards are:
Sunnybrook Health Sciences Centre, for Kullervo Hynynen's low-cost focused ultrasound system. This system can find and destroy tumors without surgery, increasing quality of life and lowering the cost of treatment for patients with inoperable bone and liver cancer. Hynynen will use the investment from OICR to develop a complete prototype and perform pre-clinical testing of the new system.
OncoTek Drug Delivery Inc., for Joseph Elliot's preclinical development of PoLi-PTX, an intraperitoneal ovarian cancer therapy invented by Drs. Christine Allen and Micheline Piquette-Miller at the University of Toronto, which would deliver localized cancer killing agents to the abdominal cavity with fewer side effects than traditional systemic chemotherapy.
"Both these therapies promise to provide patients and physicians with new tools to treat cancer that are less expensive or more effective than traditional treatments while vastly improving patients' quality of life," said Dr. Tom Hudson, President and Scientific Director of OICR. "This investment will help to make both therapies a reality."...cont'd
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
Abstract/full free pdf: published March 11, 2010
Women who were at least 18 years old with recurrent, histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube cancer; measurable disease as defined
by RECIST; had received at least 1 but fewer than 4 prior platinum-containing chemotherapy regimens; at least 1 prior paclitaxel-containing regimen; and considered platinum refractory or resistant disease according to the standard GOG criteria (had progressed during or had persistent disease after completion of platinum-based therapy or had a platinum-free interval of < 6 months) were enrolled. There were no additional limits to lines of therapy.
Difficulty Accepting a Terminal Prognosis Linked with Depression, Anxiety, and Suffering -- A Cancer Journal for Clinicians
Note: VERY SENSITIVE TOPIC Dissenting Opinion
Not all clinicians agree with the foregoing interpretations of these findings. "I've certainly seen people who denied dying up to their last breath and somehow never accepted it," Dr. Holland tells CA. "Were they more upset? I'm not sure."
She cautioned against allowing the findings by Dr. Thompson and colleagues to set a tone in which nonaccepting patients are viewed as dysfunctional. Death is as individualized as is life, she argues, invoking Sir William Osler, who said "Basically, people die as they have lived."
Note: variety of different types of studies/locations